Brigham and Women's Hospital Report issue

Academic/Hospital Phase 2
Founded: Boston Massachusetts United States (1994)

Organization Overview

First Clinical Trial
2011
NCT01377987
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

David Andrew Wellman | David Leaf | Ivan O. Rosas | Jessica Harder, MD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Critical Illness (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Disease (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6